The treatment of relapsed lymphoma remains challenging. Despite conventional treatment approaches, such as chemotherapy and radiation therapy, the disease persists in many patients. The goal of this study is to find the highest dose of an investigational drug called CUDC-907 that can be given safely in patients with relapsed lymphoma that has persisted or returned despite standard therapy, and to evaluate its potential effects against lymphoma.
CUDC-907 is designed to reduce cancer growth by inhibiting two enzymes inside the lymphoma cells: histone deacetylase (HDAC) and PI3 kinase (PI3K). Drugs that target just one of these pathways at a time have shown to be effective for reducing lymphoma cell growth, but CUDC-907 is different in that it targets both pathways, making it potentially more effective. CUDC-907 is a tablet that is taken orally (by mouth).